Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
Enriqueta Felip1, Rafael Rosell21Vall d’Hebron University Hospital, Barcelona, Spain; 2Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, SpainAbstract: NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of can...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2008-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|